Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications

Diabetes Therapy

Volumn 2, Issue 1, 2011, Pages 29-39

  Unger, Jeffrey R ^a,b   Parkin, Christopher G ^b  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Health Management Resources Inc   (United States)

Author keywords

cardiovascular risks; exenatide; gastric inhibitory polypeptide; glucagon like peptide 1; liraglutide; postprandial glycemia; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR STIMULATING AGENT; INCRETIN; INSULIN; INSULIN GLARGINE; LIPID; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NEUTRALIZING ANTIBODY; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY TITER; APOPTOSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CELL PROLIFERATION; CELL SURVIVAL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; DYSPEPSIA; EXERCISE; EXOCYTOSIS; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INDIVIDUALIZATION; INJECTION SITE REACTION; INSULIN SYNTHESIS; KIDNEY FAILURE; LIPID BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MULTICENTER STUDY (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATIENT CARE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; REVIEW; RISK REDUCTION; RODENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THYROID MEDULLARY CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA; VOMITING; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 79953214058     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-010-0013-5     Document Type: Review

References (32)

1. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964; 24: 1076-1082.
2. Nauck MA, Busing M, Orskov C, et al. Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol. 1993; 30: 39-45.
3. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009; 297: 127-136.
4. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001; 86: 3717-3723.
5. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3: 153-165.
6. Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151: 1473-1486.
7. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000; 85: 3575-3581.
8. Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud. 2008; 5: 73-94.
9. Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008; 24: 2943-2952.
10. Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep. 2010; 10: 124-132.
11. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003; 26: 2370-2377.
12. Victoza [package insert]. Princeton, NJ: Novo Nordisk, Inc. January 20, 2010.
13. Steensgaard DB, Thomsen JK, Olsen HB, Knudsen SM. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide [abstract]. Diabetes. 2008; 57(suppl. 1): A164. Abstract 552-P.
14. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002; 45: 195-202.
15. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374: 39-47.
16. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010; 33: 1300-1303.
17. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. January 1, 2009.
18. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc. January 12, 2007.
19. Unger J. Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes. Mellitus Mayo Clinic Proceedings. 2010; 85: S38-S49.
20. Buse J, Montanya D, Sesti G, et al. Frequency and magnitude of antibody formation are lower with liraglutide than exenatide: LEAD-6 results. Paper presented at: 70th Scientific Sessions of the American Diabetes Association; June 25-29, 2010; Orlando, FL. Abstract 0676-P.
21. Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004; 145: 2653-2659.
22. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90: 5991-5997.
23. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003; 52: 1786-1791.
24. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med. 2008; 25: 152-156.
25. Bunck MC, Diamant M, Cornér A, et al. Oneyear treatment with exenatide improves betacell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009; 32: 762-768.
26. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009; 32: 1224-1230.
27. Mafong DD, Henry RR. The role of incretins in cardiovascular control. Curr Hypertens Rep. 2009; 11: 18-22.
28. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24: 275-286.
29. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30: 1608-1610.
30. Plutzky J, Garber A, Falahati A, Taft AD, Paultzer NR. Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis. Paper presented at: 20th World Diabetes Congress; October 18-22, 2009; Montreal, Canada. Abstract O-0542. Available at: www. diabetes. ca. Accessed August 15, 2010.
31. Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, Pijl H. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2010; 299: E318-E324.
32. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010; 362: 774-777.